Aethlon Medical, Inc. has announced that the independent Data Safety Monitoring Board overseeing its ongoing clinical trial, AEMD-2022-06, has completed a scheduled safety review. The board has recommended advancing to the next patient cohort without any modifications. This trial, titled "Safety, Feasibility, and Dose-Finding Study of Aethlon Hemopurifier in Patients with Solid Tumors Who Have Stable or Progressive Disease While on a Treatment That Includes Pembrolizumab or Nivolumab," is assessing the Hemopurifier's safety, feasibility, and optimal dosing. The primary endpoint is the incidence of adverse events and clinically significant changes in safety laboratory tests. Aethlon Medical aims to use the findings to inform the design of a future efficacy and safety study required for regulatory approval. Enrollment for Cohort 2 is now open, with participants set to receive two Hemopurifier treatments over a one-week period at three clinical sites in Australia. The trial intends to enroll approximately 9 to 18 patients. Results from this study will be presented in the future as the trial progresses.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。